XORTX Therapeutics Inc.

NasdaqCM:XRTX Stock Report

Market Cap: US$3.5m

XORTX Therapeutics Management

Management criteria checks 3/4

XORTX Therapeutics' CEO is Allen Davidoff, appointed in Jan 2018, has a tenure of 8.08 years. total yearly compensation is $416.99K, comprised of 82.4% salary and 17.6% bonuses, including company stock and options. directly owns 1.82% of the company’s shares, worth $62.78K. The average tenure of the management team and the board of directors is 4.2 years and 5.2 years respectively.

Key information

Allen Davidoff

Chief executive officer

US$417.0k

Total compensation

CEO salary percentage82.38%
CEO tenure8.1yrs
CEO ownership1.8%
Management average tenure4.2yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

XORTX completes positive pre-phase 3 meeting with the FDA

Sep 19

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

Aug 22

XORTX jumps over 100% after early encouraging data for rare disease therapy

Jul 13

CEO Compensation Analysis

How has Allen Davidoff's remuneration changed compared to XORTX Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$2m

Jun 30 2025n/an/a

-US$2m

Mar 31 2025n/an/a

-US$993k

Dec 31 2024US$417kUS$344k

-US$3m

Sep 30 2024n/an/a

-US$737k

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

-US$3m

Dec 31 2023US$322kUS$255k

-US$2m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$7m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$321kUS$273k

-US$8m

Sep 30 2022n/an/a

US$1m

Jun 30 2022n/an/a

-US$3m

Mar 31 2022n/an/a

-US$2m

Jan 01 2022n/an/a

-US$2m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$204kUS$154k

-US$1m

Sep 30 2020n/an/a

-US$767k

Jun 30 2020n/an/a

-US$536k

Mar 31 2020n/an/a

-US$362k

Dec 31 2019US$161kUS$148k

-US$485k

Compensation vs Market: Allen's total compensation ($USD416.99K) is about average for companies of similar size in the US market ($USD568.82K).

Compensation vs Earnings: Allen's compensation has increased whilst the company is unprofitable.

CEO

Allen Davidoff (65 yo)

8.1yrs
Tenure
US$416,989
Compensation

Dr. Allen Warren Davidoff, Ph.D. is Founder of XORTX Therapeutics Inc. (formerly known as XORTX Pharma Corp.) and has been its Chief Executive Officer and President since January 9, 2018. Dr. Davidoff serv...

Leadership Team

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder8.1yrsUS$416.99k1.82%
$ 62.8k
Michael Bumby
Chief Financial Officer1.2yrsUS$6.72kno data
Stephen Haworth
Chief Medical Officer4.6yrsUS$120.19k0%
$ 0
Stacy Evans
Chief Business Officer3.3yrsUS$157.50kno data
Nick Rigopoulos
Director of Communicationsno datano datano data
David Sans
Director of Corporate Development5.5yrsno datano data
David MacDonald
Consultant of Clinical Operations3.8yrsno datano data
Charlotte May
Corporate Secretaryno datano datano data
4.2yrs
Average Tenure
61.5yo
Average Age

Experienced Management: XRTX's management team is considered experienced (4.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Allen Davidoff
Founder8.1yrsUS$416.99k1.82%
$ 62.8k
Paul Van Damme
Independent Director8.1yrsUS$17.24k0.0046%
$ 160.7
Anthony Giovinazzo
Independent Chair of the Board3.7yrsUS$129.93k0.14%
$ 4.8k
Richard Johnson
Member of Clinical Advisory Boardno datano datano data
Raymond Pratt
Independent Director4.2yrsUS$14.02k0%
$ 0
Henk E. D. ter Keurs
Member of Scientific Advisory Boardno datano datano data
Federico Maese
Member of Clinical Advisory Board7.3yrsno datano data
Petter Bjornstad
Member of Clinical Advisory Board7.3yrsno datano data
Anjay Rastogi
Member of the Clinical Advisory Board5.9yrsno datano data
Charles Edelstein
Member of the Advisory Board4.5yrsno datano data
Ronald Perrone
Member of Clinical Advisory Board1.9yrsno datano data
Krysta Davies Foss
Directorless than a yearno data0.040%
$ 1.4k
5.2yrs
Average Tenure
71yo
Average Age

Experienced Board: XRTX's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/05 02:10
End of Day Share Price 2026/02/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

XORTX Therapeutics Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners